EU/3/15/1593
Table of contents
About
On 14 December 2015, orphan designation (EU/3/15/1593) was granted by the European Commission to Janssen-Cilag International N.V., Belgium, for imetelstat sodium for the treatment of myelofibrosis.
The sponsorship was transferred to Parexel International GmbH, Germany, in August 2019.
Key facts
Active substance |
Imetelstat sodium
|
Disease / condition |
Treatment of myelofibrosis
|
Date of first decision |
14/12/2015
|
Outcome |
Positive
|
EU designation number |
EU/3/15/1593
|
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Sponsor's contact details
Parexel International GmbH
Spandauer Damm 130
Charlottenburg
14050 Berlin
Germany
E-mail: ivan.tommasini@parexel.com
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.